为了确定非小细胞肺癌（NSCLC）患者是否需要全面支持，我们研究了与未接受指南推荐治疗相关的患者和与疾病相关的易感因素之间的关联。我们在丹麦肺癌登记处识别了2013年至2018年期间有着《1-3分规范状态》的14,597名非小细胞肺癌（NSCLC）患者。使用多元 logistic 回归模型估计按照分期、合并症、年龄、规范状态、离医院的距离、同住状况、教育程度和酗酒情况接受指南推荐治疗的几率比（OR）和95%置信区间（CI）。21%的分期 I-IIIA NSCLC 患者没有接受治愈性治疗，而有10%的分期 IIIB-IV NSCLC 患者没有接受任何肿瘤学治疗。与接受治愈性治疗几率降低相关的因素包括：晚期（OR = 0.45; CI = 0.42-0.49）、体征合并症（OR = 0.72; CI = 0.63-0.83）、年龄≥80岁（OR = 0.59; CI = 0.55-0.64）、分期 I-IIIA NSCLC 患者的规范状态为 2（OR = 0.33; CI = 0.28-0.39）和居住独自一人（OR = 0.79; CI = 0.69-0.90）。对于分期 IIIB-IV NSCLC 患者来说，结果类似，尽管还观察到与离医院较远的距离有显著关联（OR = 0.71; CI = 0.58-0.86）。有几个因素与未接受指南推荐的NSCLC治疗有关，年龄、规范状态、合并症和分期被认为最具预测性，应努力开展支持措施，改善易感肺癌患者对最佳一线治疗的依从性。

To identify non-small-cell lung cancer (NSCLC) patients in need of comprehensive support, we examined the association between patient and disease-related factors of vulnerability related to not receiving guideline-recommended treatment.We identified 14,597 non-small-cell lung cancer (NSCLC) patients with performance status <3 during 2013-2018 in the Danish Lung Cancer Registry. Multivariate logistic regression models were used to estimate Odds Ratios (ORs) and 95% confidence intervals (CIs) for receiving guideline-recommended treatment according to stage, comorbidities, age, performance status, long distance to hospital, cohabitation status, education and alcohol abuse.21% of stage I-IIIA NSCLC patients did not receive curative treatment while 10% with stage IIIB-IV did not receive any oncological therapy. Factors associated with reduced likelihood of receiving curative treatment included: advanced stage (OR = 0.45; 95% CI = 0.42-0.49), somatic comorbidity (OR = 0.72; 95% CI = 0.63-0.83), age ≥ 80 years (OR = 0.59; 95% CI = 0.55-0.64), performance status = 2 (OR = 0.33; 95% CI = 0.28-0.39) and living alone (OR = 0.79; 95% CI = 0.69-0.90). Results were similar for stage IIIB-IV NSCLC patients, although a statistically significant association was also seen for long distances to the hospital (OR = 0.71; 95% CI = 0.58-0.86).Several factors are associated with not receiving guideline-recommended NSCLC treatment with age, performance status, comorbidity and stage being most predictive of no treatment receipt. Efforts should be made to develop support for vulnerable lung cancer patients to improve adherence to optimal first-line therapy.